Nirsevimab Reduced Hospitalizations for Infants With RSV
The monoclonal antibody nirsevimab (Beyfortus) reduced hospitalizations among infants with respiratory syncytial virus (RSV)-associated lower respiratory tract infection, the randomized, pragmatic HARMONIE trial showed. In over 8,000 infants included in the study, 0.3% who received nirsevimab were hospitalized for RSV-associated lower respiratory tract infection compared with 1.5% of those who received standard care, which corresponded […]
CDC Advisors Back Therapeutic to Prevent RSV in Infants
The CDC’s Advisory Committee on Immunization Practices (ACIP) voted unanimously — 10 to 0 — in favor of nirsevimab (Beyfortus) for protecting a wide swath of at-risk infants from respiratory syncytial virus (RSV). At a meeting on Thursday, ACIP recommended that all infants younger than 8 months who are born during or approaching their first […]